- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04003480
FRAME, External Support for Lower Limb Autologous Grafts
February 3, 2025 updated by: Vascular Graft Solutions Ltd.
Prospective, Multicenter Study Evaluating the Performance and Safety of FRAME, External Support for Lower Limb Autologous Grafts.
30 patients will be enrolled in a prospective, multi-center, one-arm study, enrolling patients with claudication and chronic limb ischemia scheduled for lower limb venous bypass grafting on clinical grounds with single segment autologous saphenous vein.
Subjects will be followed for 5 years, with follow up visits at 1, 3, 6, 12 months, 2, 3, 4, 5, years post operation.
Study Overview
Status
Suspended
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Indiana
-
Fort Wayne, Indiana, United States, 46804
- Lutheran Hospital of Indiana
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- University of Maryland Baltimore
-
-
New York
-
New York, New York, United States, 10029
- Mount Sinai Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
14 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patient scheduled for infrainguinal peripheral artery bypass surgery with single segment autogenous saphenous vein.
- Rutherford classification 3-6
- Adequate revascularization target defined as an infrainguinal arterial segment distal to the area of stenosis/occlusion which can support a distal anastomosis of a surgical bypass.
- Patient is able and willing to give their informed written consent.
- Patient is able and willing to comply with study follow up requirements.
- Patient is ≥ 18 years of age
Exclusion Criteria:
- Patients indicated for endovascular treatment
- Prior surgical bypass procedure in ipsilateral lower limb.
- Active ulcer/infection/gangrene at the intended distal anastomosis site.
- Severe vein varicosity
- Saphenous vein with external pressurized diameter of less than 3.5 mm or more than 8 mm.
- Spliced vein technique
- In-situ vein technique
- Pedal/plantar distal anastomosis
- Planned above ankle amputation on ipsilateral limb within 4 weeks of index procedure.
- Patients with history of hypercoagulable conditions.
- Patients with significant stenoses distal to the planned anastomotic site and any other known conditions that could adversely affect graft patency.
- Concomitant life-threatening disease likely to limit life expectancy to less than 2 years.
- Contraindication to recommended study medications
- Participating in any other investigational study for either drug or device which can influence collection of valid data under this study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: FRAME
Vein graft to be treated with FRAME
|
External support for vein grafts in peripheral bypass surgery
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Primary patency
Time Frame: 12 months
|
Freedom of vein graft from occlusion and clinically driven target lesion revascularization as measured by Doppler Ultrasound
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
December 31, 2026
Primary Completion (Estimated)
December 1, 2028
Study Completion (Estimated)
December 1, 2029
Study Registration Dates
First Submitted
June 27, 2019
First Submitted That Met QC Criteria
June 27, 2019
First Posted (Actual)
July 1, 2019
Study Record Updates
Last Update Posted (Actual)
March 25, 2025
Last Update Submitted That Met QC Criteria
February 3, 2025
Last Verified
February 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CD0177
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Arterial Disease
-
University of NebraskaRecruitingPeripheral Arterial Disease | Peripheral Vascular Diseases | Peripheral Arterial Occlusive Disease | Peripheral Artery DiseaseUnited States
-
Marissa JarosinskiTerminatedPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery Disease | Clopidogrel, Poor Metabolism of | Artery DiseaseUnited States
-
OrbusNeichEucatech AG; Centre Européen de Recherche CardiovasculaireRecruitingPeripheral Arterial Disease | Peripheral Arterial Occlusive DiseaseSpain, Singapore, Belgium, Germany
-
CID S.p.A.Meditrial Europe Ltd.Not yet recruitingPeripheral Arterial Occlusive Disease | Peripheral Artery DiseaseItaly
-
Wroclaw Medical UniversityPoznan University of Medical Sciences; Military Institute of Medicine National...RecruitingPeripheral Arterial Disease(PAD)Poland
-
BayerCompleted
-
University of NebraskaRecruitingPeripheral Arterial Disease | Peripheral Vascular Disease | Peripheral Artery Disease | Peripheral Artery Occlusive DiseaseUnited States
-
Stanford UniversityTerminatedPAD - Peripheral Arterial Disease | PVD- Peripheral Vascular DiseaseUnited States
-
Vascuros Medical Pte LtdNovella ClinicalUnknownPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery DiseaseSingapore, Belgium, Germany
-
Western Vascular Institute, IrelandRecruitingPeripheral Arterial Occlusive DiseaseIreland
Clinical Trials on FRAME
-
Universitaire Ziekenhuizen KU LeuvenCompleted
-
Guangzhou Blood CenterCompleted
-
Boston CollegeCompleted
-
Guangzhou Blood CenterCompleted
-
Odense University HospitalUniversity of Southern DenmarkRecruitingQuality of Life | Physical Activity | Physical Disability | Physical Function | ParticipationDenmark
-
Oslo University HospitalSahlgrenska University Hospital, SwedenCompleted
-
Queen Margaret UniversityMultiple Sclerosis Society of Great BritainCompletedMultiple SclerosisUnited Kingdom
-
Yale-NUS CollegeCompleted
-
Tianjin Eye HospitalNot yet recruitingMyopia, ProgressiveChina
-
Tianjin Eye HospitalCompleted